Huda Y Zoghbi Regeneron Pharmaceuticals, Inc. (REGN) insider trading activity

REGN Quotes by TradingView

Huda Y Zoghbi is Director of REGENERON PHARMACEUTICALS, INC.. Currently has a direct ownership of 1,548 shares of REGN, which is worth approximately $1.1 Million. The most recent transaction as insider was on Jan 02, 2025, when has been sold 166 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 1.55K
24.14% 3M change
24.14% 12M change
Total Value Held $1.1 Million

Huda Y Zoghbi Transaction History

Date Transaction Value Shares Traded Shares Held Form
Jan 02 2025
BUY
Grant, award, or other acquisition
-
166 Added 9.68%
1,548 Common Stock
Jan 02 2024
SELL
Open market or private sale
$1,005,300 $900.0 p/Share
1,117 Reduced 47.25%
1,247 Common Stock
Jan 02 2024
BUY
Grant, award, or other acquisition
-
135 Added 8.9%
1,382 Common Stock
Jan 02 2024
BUY
Exercise of conversion of derivative security
$437,774 $391.92 p/Share
1,117 Added 32.09%
2,364 Common Stock
Oct 13 2023
SELL
Open market or private sale
$850,000 $850.0 p/Share
1,000 Reduced 44.5%
1,247 Common Stock
Oct 13 2023
BUY
Exercise of conversion of derivative security
$391,920 $391.92 p/Share
1,000 Added 30.8%
2,247 Common Stock
Jan 03 2023
BUY
Grant, award, or other acquisition
-
165 Added 11.69%
1,247 Common Stock
Mar 16 2022
SELL
Open market or private sale
$1,350,000 $675.0 p/Share
2,000 Reduced 64.89%
1,082 Common Stock
Mar 16 2022
BUY
Exercise of conversion of derivative security
$783,840 $391.92 p/Share
2,000 Added 39.35%
3,082 Common Stock
Jan 03 2022
BUY
Grant, award, or other acquisition
-
191 Added 15.0%
1,082 Common Stock
Sep 14 2021
SELL
Open market or private sale
$648,700 $650.0 p/Share
998 Reduced 52.83%
891 Common Stock
Sep 14 2021
BUY
Exercise of conversion of derivative security
$391,136 $391.92 p/Share
998 Added 34.57%
1,889 Common Stock
Sep 13 2021
SELL
Open market or private sale
$1,302 $651.1 p/Share
2 Reduced 0.22%
891 Common Stock
Sep 13 2021
BUY
Exercise of conversion of derivative security
$784 $391.92 p/Share
2 Added 0.22%
893 Common Stock
Jan 04 2021
BUY
Grant, award, or other acquisition
-
248 Added 21.77%
891 Common Stock
Jul 07 2020
SELL
Open market or private sale
$1,108,900 $650.0 p/Share
1,706 Reduced 72.63%
643 Common Stock
Jul 07 2020
BUY
Exercise of conversion of derivative security
$668,615 $391.92 p/Share
1,706 Added 42.07%
2,349 Common Stock
Jun 11 2020
SELL
Open market or private sale
$1,066,250 $625.0 p/Share
1,706 Reduced 72.63%
643 Common Stock
Jun 11 2020
BUY
Exercise of conversion of derivative security
$668,615 $391.92 p/Share
1,706 Added 42.07%
2,349 Common Stock
Jun 10 2020
SELL
Open market or private sale
$1,042,587 $611.13 p/Share
1,706 Reduced 72.63%
643 Common Stock
Jun 10 2020
BUY
Exercise of conversion of derivative security
$668,615 $391.92 p/Share
1,706 Added 42.07%
2,349 Common Stock
May 07 2020
SELL
Open market or private sale
$2,904,106 $567.43 p/Share
5,118 Reduced 88.84%
643 Common Stock
May 07 2020
BUY
Exercise of conversion of derivative security
$2,005,846 $391.92 p/Share
5,118 Added 47.04%
5,761 Common Stock
HYZ

Huda Y Zoghbi

Director
Tarrytown, NY

Track Institutional and Insider Activities on REGN

Follow REGENERON PHARMACEUTICALS, INC. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells REGN shares.

Notify only if

Insider Trading

Get notified when an Regeneron Pharmaceuticals, Inc. insider buys or sells REGN shares.

Notify only if

News

Receive news related to REGENERON PHARMACEUTICALS, INC.

Choose your preferred platform and Sign Up 👇 Telegram Email
Track Activities on REGN